The Cost of Adrenal Insufficiency in England—Analysis of NHS HES Data
Clinical Endocrinology · 2025
DOI: 10.1111/cen.15207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Robert D Murray und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. Hauptthemen laut MEDLINE: Adrenal Insufficiency, Health Care Costs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This work was funded by ADVANZ PHARMA and medical writing assistance was provided by Janet Wild on behalf of CSL, under the supervision of the authors..
Abstract (Originalsprache)
Background
Despite steroid replacement therapy, patients with adrenal insufficiency (AI) experience excessive infections and related hospital admissions. However, data examining the evolution of admissions, healthcare resources utilisation and cost burden is sparce.
Design
Analysis of National Hospital Episode Statistics (HES) data set which contains details of all admissions and outpatient appointments at NHS hospitals in England. Methods and Measurements Spells spanning financial years 2018/19 to 2022/23, focusing on HES codes E27.1 (Primary Adrenocortical Insufficiency; PAI) [ n = 57,125], E27.2 (Addisonian Crisis; AC) [ n = 12,640] and E27.4 (Other and Unspecified AI; UAI) [ n = 79,965] were analysed for admissions, main diagnosis, bed‐days, costs, follow‐up, and readmissions.
Results
Over the study period, admissions for AC remained stable; admissions involving UAI increased, whereas PAI admissions reduced transiently during COVID‐19. Mean length of stay for AC increased from 5.1 to 6.8 days (34%). Patients with primary pneumonia and AI had longer hospital stays than those without AI and were more likely to require critical care. Mean cost per hospital stay increased, rising 25% for AC since 2019/20, reaching £2959 per stay. 10% of patients had >1 non‐elective readmission within 12 months. Endocrinologist follow‐up was lower than expected. Centres treating > 225 spells/year reviewed 20−46% of AI patients within 26 weeks of admission, and only 46% with a main diagnosis of AC in 2022/23.
Conclusions
AI admissions have increased since 2018/19. Bed‐days and cost for AC episodes have also risen. Patients with concomitant AI were more likely to have longer stays and be re‐admitted. Endocrinology follow‐up appears surprisingly low despite published guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
- Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK.
- Global Market Access, Advanz Pharma, London, UK.
- CSL (CompuFile Systems Ltd), Godalming, UK.
- Global Medical Affairs, Advanz Pharma, London, UK.
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
Förderung
- This work was funded by ADVANZ PHARMA and medical writing assistance was provided by Janet Wild on behalf of CSL, under the supervision of the authors.
Zitieren
APA
Murray, R. D., Ruiz-Casas, L., Beckett, M., Polifka, J., Cure, S., Ritz, B., & Wass, J. (2025). The Cost of Adrenal Insufficiency in England—Analysis of NHS HES Data. Clinical Endocrinology. https://doi.org/10.1111/cen.15207
Vancouver
Murray RD, Ruiz-Casas L, Beckett M, Polifka J, Cure S, Ritz B, et al. The Cost of Adrenal Insufficiency in England—Analysis of NHS HES Data. Clinical Endocrinology. 2025. doi:10.1111/cen.15207
BibTeX
@article{Murray2025,
author = {Murray, Robert D and Ruiz-Casas, Leonardo and Beckett, Matthew and Polifka, Juergen and Cure, Sandrine and Ritz, Beate and Wass, John},
title = {The Cost of Adrenal Insufficiency in England—Analysis of NHS HES Data},
journal = {Clinical Endocrinology},
year = {2025},
doi = {10.1111/cen.15207}
}
EUVIMED